Impact of patient choice and hospital competition on patient outcomes after prostate cancer surgery: A national population‐based study

Ajay Aggarwal(King's College London), Jan van der Meulen(London School of Hygiene & Tropical Medicine), Noel W. Clarke(The Christie NHS Foundation Trust), Kate Walker(Royal College of Surgeons of England), Daniel Lewis(The Huntington Library, Art Museum, and Botanical Gardens), Richard Sullivan(Precision Spine (United States)), Paul Cathcart(National Health Service), Arunan Sujenthiran(Royal College of Surgeons of England)
Cancer
February 1, 2019
10.1002/cncr.31987
Cited by 21

Related Papers

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
|The Lancet|2015|2k
The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study
|The Lancet Oncology|2020|1.9k
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
|New England Journal of Medicine|2017|1.8k
Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017
|European Urology|2017|644
The Lancet Commission on diagnostics: transforming access to diagnostics
|The Lancet|2021|442